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Abstract: Using pregnenolone and 7-deoxycholic acid as starting materials, some 
17-acetamidoandrostane and N,N-dimethyl-7-deoxycholic amide derivatives were 
synthesized. The cytotoxicity of the synthesized compounds was tested in vitro against two 
tumor cell lines: SGC 7901 (human gastric carcinoma) and Bel 7404 (human liver 
carcinoma). The result showed that the blockage of the interaction of the amide group with 
outside groups might cause a decrease of the cytotoxicity, and an O-benzyloximino group at 
the 3-position of N,N-dimethyl-7-deoxycholic amide could enhance the cytotoxic activity of 
the compound. The information obtained from the studies provides the structure-activity 
relationship for these compounds and may be useful for the design of novel 
chemotherapeutic drugs. 
Keywords: pregnenolone; 17-acetamidoandrostane; N,N-dimethyl-7-deoxycholic amide; 
antiproliferative activity 
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1. Introduction 
Steroidal compounds display a variety of biological functions and play a very important role in  
life [1–3]. Azahomosteroids are also a class of steroid compounds which were synthesized and 
modified in order to increase the biological activity of steroids. These compounds have been tested 
successfully as anti-cancer drugs against several types of cancer cells [4–8]. Some researchers 
indicated that the presence of the characteristic group (-NH-CO-) in the aza-homosteroid molecule had 
been proven to be important in lowering the acute toxicity and improving antitumour activity of the 
compound in cancer research [9,10]. 
Several new steroidal lactams with the introduction of NHCO groups on the A-ring, C-ring or 
D-ring of the steroidal nucleus were synthesized and assayed in our group [11–14]. We found that 
these compounds displayed distinct cytotoxicity against different cancer cells, for instance, the 
steroidal lactam compounds I and II (Figure 1) displayed distinct cytotoxicity against some cancer 
cells through effective induction of cancer cell apoptosis by activation of the intrinsic pathway [15]. 
Figure 1. The structure of compounds I–IV. 
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A survey of the literature suggested steroidal compounds with a NHCO group in the side chain 
exhibit some valuable biological activities, such as cytotoxicity and antibacterial properties. For 
example, finasteride, dutasteride and PNU-157706 [16,17], used as clinical benign prostatic 
hyperplasia drugs, have a NHCO group in their branch chain. In order to further evaluate the 
antiproliferative activity of new steroidal derivatives and study their structure-activity relationships, 
some 17-acetamidoandrostane (Scheme 1) and N,N-dimethyl-7-deoxycholic amide derivatives 
(Scheme 2) with a NHCO group in their side chain were designed and synthesized. Their 
antiproliferative activities were tested in vitro against two tumor cell lines: SGC 7901 (human gastric 
carcinoma) and Bel 7404 (human liver carcinoma).  
Here, the N,N-dimethyl-7-deoxycholic amide (III) has a similar atom rank of the side chain of as 
24-methylenecholest-4-en-3β,6β-diol (IV), which is a polyhydroxylsterol obtained from the soft coral 
Alcyonium patagonicum that showed potent cytotoxicity to murine leukemia cell with an IC50 value of 
1 µg/mL [18], except for different atoms substituted in the 25- and 28-positions of the side chain. 
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Scheme 1. Synthetic procedures of 17-acetamido-androst-5-en derivatives. 
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Reagents and conditions: (i) Ac2O/Pyridine/r.t., 24 h; (ii) NH2OH.HCl/NaOAc.3H2O/95% 
CH3CH2OH, 60 °C, 2h; (iii) SOCl2/THF, r.t., 2 h; (iv) 13% K2CO3/CH3OH/reflux, 4 h; (v) Jones’ 
reagent/acetone/r.t., 2 h; (vi) NaBH4/CH3OH, r.t., 30 min; (vii) NiCl2·6H2O/NaBH4. 
Scheme 2. Synthetic procedures of N,N-dimethyl-7-deoxycholic amide derivatives. 
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Reagents and conditions: (a) Jones’ reagent, (CH3)2CO, 0 °C; (b) Toluene, (CO)2Cl2, Py/(CH3)2NH 
(33%); (c) NaBH4/CH3OH; (d) Ac2O/Pyridine/r.t., 24 h; (e) NH2NHCSNH2/EtOH, 80 °C.  
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2. Results and Discussion 
2.1. Chemistry 
Scheme 1 outlines the synthetic procedures for compounds 4–8. First, the 3β-hydroxy group of 
pregnenolone (1) was protected by acetylation, then oximation of 3β-acetoxypregnenolone (2) was 
performed using NH2OH·HCl and NaOAc·3H2O to give compound 3. Compound 4 was generated by 
Beckmann rearrangement of 3 with SOCl2/THF. Afterwards, compound 5 was obtained via the 
deacetylation of 4 with alcoholic K2CO3. Compound 6 was prepared by the oxidation of 5 with Jones’ 
reagent and multiple extraction because of better water solubility of compound 6. Lastly, compound 6 
was converted to compounds 7 and 8 by selective reduction using NaBH4 under different conditions. 
Synthetic procedures to obtain N,N-dimethyl-7-deoxycholic amide derivatives 11–14 are outlined in 
Scheme 2. First, 3,12-dioxo-7-deoxycholic acid (10) was obtained by oxidation of 7-deoxycholic acid (9) 
with Jones’ reagent. Then, the reaction of 10 with (CO)2Cl2 and (CH3)2NH in toluene gave 
N,N-dimethyl-3,12-dioxo-7-deoxycholic amide (11). The structure of compound 11 had been confirmed 
by its IR, NMR and MS spectra. In the IR spectrum, the disappearance of the broad absorption peak at 
3,200–2,500 cm−1 showed that the COOH functional group had been converted to another group. The 
chemical shifts of 2.923 and 2.985 ppm (single peak) in the 1H-NMR confirmed the existence of the 
CON(CH3)2 moiety. Next, the functional groups on the 3-position were modified in order to compare the 
relative antiproliferative activities of different groups. Compound 11 was converted to 
N,N-dimethyl-3-hydroxy-12-oxo-7-deoxycholic amide (12) by selective reduction using NaBH4. 
Finally, compound 13 was produced by the esterification of the 3-hydroxy group of 12, and compound 
14 was obtained by the reaction of 12 with thiosemicarbazide. 
To further determine the effect of the 3-substituent groups of N,N-dimethyl-7-deoxycholic  
amide derivatives on the cytotoxic activity, compounds 15–18 with different 3-substitutent groups  
were prepared. Similarly, the reaction of compound 11 with hydroxylamine hydrochloride, 
thiosemicarbazide, CH3ONH2·HCl or PhCH2ONH2·HCl afforded the corresponding products 15, 16, 17 
or 18, respectively (Scheme 3). 
Scheme 3. Synthetic procedures of N,N-dimethyl-7-deoxycholic amide derivatives. 
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Reagents and Conditions: (a) NH2OH·HCl/95%EtOH, CH3COONa, 70 °C;  
(b) NH2NHCSNH2/EtOH, 80 °C; (c) CH3ONH2·HCl/95%EtOH, CH3COONa, 70 °C;  
(d) PhCH2ONH2·HCl/95% EtOH, CH3COONa, 70 °C. 
15: R = NOH, 16: R = NNHCSNH2 
17: R = NOCH3, 18: R = NOCH2C6H5
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2.2. In Vitro Evaluation of the Antiproliferative Activity 
2.2.1. Cell Culture and Assay for Cell Viability 
SGC 7901 (human gastric carcinoma) and Bel 7404 (human liver carcinoma) cell lines were obtained 
from Guangxi Traditional Chinese Medical University. Cells were grown in RPMI-1640 supplemented 
with 10% cosmic calf serum (Hyclone, Beijing, China) and antibiotics in a humidified atmosphere of 5% 
CO2 at 37 °C. The viability of these cells was determined using the colorimetric CellTiter 96 aqueous 
Cell Proliferation Assay (MTT) according to the instructions provided by the manufacturer (Promega, 
Madison, WI, USA). Briefly, cells (1~3 × 104 cells per well) were seeded in 96 wells plates. An equal 
amount of DMSO was added to the cells used as negative controls. All were treated in triplicate. One day 
after seeding, the cells were treated with or without different concentration of each compound and 
reincubated for 72 h. After the cells were washed with sterile phosphate buffer saline (PBS), 190 µL of 
RPMI-1640 and 10 µL of the tetrazolium dye (MTT) (5 mg/mL) solution were added to each well, and 
the cells were incubated for an additional 4 h. The medium was discarded; 200 µL of DMSO was added 
to dissolve the purple formazan crystals formed. The absorbance (A) at 492 nm was measured using a 
MULTISCAN MK3 analysis spectrometer (Thermo Scientific, Shanghai, China). The results were 
summarized as IC50 values in µ mol/L in Table 1. 
Table 1. In vitro antiproliferative activities (IC50 in μmol/L) of the compounds 3–18. 
Componuds 3 4 5 6 7 8 11 12 
SGC 7901 23.4 65.8 63.4 49.0 58.4 61.5 >100 >100 
Bel 7404 51.2 >100 >100 80.1 >100 >100 >100 >100 
Compounds 13 14 15 16 17 18 Cisplatin  
SGC 7901 >100 >100 >100 >100 >100 15.0 6.7  
Bel 7404 >100 >100 >100 >100 >100 14.4 23.2  
2.2.2. Structure-Activity Relationships 
As shown in Table 1, compound 3 with a 20-hydroximino group displayed distinct cytotoxicity 
against the two studied cancer cell lines. However, after the 20-hydroximino group of 3 was converted 
into an amide group (compounds 4–8), the antiproliferative activity of compounds was remarkably 
decreased. The result could be ascribed to the blockage of the interaction of the amide group with outside 
groups, which may be a main reason causing a decrease of the cytotoxicity because of the steric 
hindrance of the steroidal nucleus [14]. Therefore, changing the hydroximino group to the amide group 
at position-20 did not increase the cytotoxic activities of these 17-acetamidoandrost-5-ene derivatives. 
Comparing the result with the earlier studies [12,13], we can see that the cytotoxicity of the steroidal 
amide compounds is not only dependent on the structure of the side chain, but also the position of the 
CONH functional group. When the compounds had a cholesteric side chain and A-ring or B-ring was 
modified into an A-lactam [13] or a B-lactam [19], it would display distinctive cytotoxicity against the 
cancer cells. 
To investigate the effect of the 24-amide group on the biological function of the compounds, we 
synthesized some N,N-dimethyl-7-deoxycholic amide derivatives with various 3-substitutent groups 
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(compounds 11–18). Here, compounds 11–17 were almost inactive against the cancer cells. Once again, 
the reason may be the steric hindrance of N,N-dimethyl group inhibiting the affinity of the amide group 
with outside groups. Nevertheless, a 3-O-benzyloxime group played an important role in the 
cytotoxicity of compound 18 against these cancer cells. Compound 18 showed almost the same 
cytotoxicity as cisplatin to SGC 7901 and Bel 7404 cells (18: 15.0 and 14.4; cisplatin: 6.7 and 23.2 µmol/L), 
indicating that the presence of the 3-O-benzyloxime group on the compound 18 confers a positive 
effect on the cytotoxicity against these cancer cells, which provides clues the seeking more powerful 
anti-cancer drug candidates based on O-benzyloxime groups via structural optimization. 
3. Experimental 
Sterols and NaBH4 were purchased from Merck Co. (Shanghai, China) All chemicals and solvents 
were analytical grade and solvents were purified by general methods before being used. Melting points 
were determined on an X4 apparatus and were uncorrected. Infrared spectra were measured with a 
Thermo Scientific IS-10 Spectrophotometer. The 1H and 13C-NMR spectra were recorded in CDCl3 on a 
Bruker AV-300 spectrometer at working frequencies 300 and 75 MHz. Chemical shifts are expressed in 
parts per million (δ) values and coupling constants (J) in Hertz. LREIMS were recorded on a 
Thermo-DSQ instrument, while HREIMS were measured on a Agilent 6210 TOFMS instrument. 
3-Acetoxy-17-acetamidoandrost-5-ene (4) and 3,12-dioxydeoxycholic acid (10) were prepared 
according to the literature [6] and [20], respectively. 
Synthesis of 3-hydroxy-17-acetamidoandrost-5-en (5). K2CO3 solution (13%, 20 mL) was added to a 
solution of compound 4 (438 mg, 3.32 mmol) in CH3OH (200 mL). The reaction mixture was heated 
under reflux for 1 h. After completion of the reaction as indicated by TLC, the solvent was removed 
under vacuum. CH2Cl2 (200 mL) was added to dissolve the solid and the resulting solution was 
washed with cold water and saturated brine. After drying over anhydrous sodium sulfate, the solvent 
was removed under reduced pressure, and the resulting crude product was purified by chromatography 
on silica gel using methanol/dichloromethane (30:1) as eluent to give 709 mg (76%) of 5 as a white 
solid. θ mp 196–197 °C; IR (KBr) ν/cm−1: 3354, 2962, 2937, 1646, 1556, 1433, 1372, 1315;  
1H-NMR (CDCl3, 300 MHz) δ: 0.721 (3H, s, 18-CH3), 1.028 (3H, s, 19-CH3), 2.002 (3H, s, N-COCH3), 
2.36–2.24 (2H, m, C4-H), 3.58–3.51 (1H, m, C3-H), 3.908 (1H, q, J = 9.0, C17-H), 5.302 (1H, brd, J = 9.9, 
N-H), 5.367(1H, dd, J = 3.6, 1.8, C6-H); 13C-NMR (CDCl3, 75 MHz) δ: 169.9 (-NHCOCH3), 140.9 
(5-C), 121.3 (6-C), 71.7 (3-C), 58.9 (17-C), 52.8 (9-C), 50.1 (13-C), 42.7 (4-C), 42.2 (14-C), 37.2 
(10-C), 36.8(1-C), 36.7 (12-C), 32.0 (8-C), 31.6 (7-C), 31.5 (16-C), 28.7 (2-C), 27.7 (15-C), 23.6 
(21-C), 20.6 (11-C), 19.4 (19-C), 11.9 (18-C); ESI-MS m/z: 332 (M+1)+. 
Synthesis of 17-acetamidoandrost-4-en-3,6-dione (6). Jones’ reagent (0.7 mL, 0.267 mol/L) was added 
dropwise to the solution of 5 (709 mg) in acetone (30 mL) in 20 min. The mixture was stirred at room 
temperature for 1 h and then neutralized with 10% K2CO3 solution. The suspension was poured over a 
silica gel column and eluted with ethyl acetate. The solvent was removed under reduced pressure. The 
residue was purified by chromatography on silica gel using methanol/dichloromethane (20:1) as 
elution to give 590 mg (80%) of 6 as white solid. θ mp 198–199 °C; IR (KBr) ν/cm−1: 3321, 2941, 2864, 
1691, 1654, 1556, 1442, 1384; 1H-NMR (CDCl3, 300 MHz) δ: 0.728 (3H, s, 18-CH3), 1.150 (3H, s, 
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19-CH3), 1.976 (3H, s, N-COCH3), 2.17–2.10 (2H, m, C7-βH and C2-αH), 2.495 (1H, dd, J = 13.8, 5.1, 
C7-αH), 2.662 (1H, dd, J = 15.9, 3.9, C2-βH), 3.937 (1H, q, J = 9.0, C17-H), 5.582 (1H, d, J = 9.0, 
N-H), 6.149 (1H, s, C4-H); 13C-NMR (CDCl3, 300 MHz) δ: 201.8 (6-C), 199.3 (3-C), 170.1 
(-NHCOCH3), 160.7 (5-C), 125.6 (4-C), 58.5 (14-C), 52.7 (17-C), 50.9 (9-C), 46.3 (13-C), 43.0 (10-C), 
39.7 (1-C), 36.3 (12-C), 35.5 (7-C), 34.3 (8-C), 33.9 (16-C), 28.2 (2-C), 23.4 (15-C), 23.2 (21-C), 20.5 
(11-C), 17.6 (19-C), 11.9 (18-C); ESI-MS m/z: 344 (M+1)+. 
Synthesis of 3,6-dihydroxy-17-acetamidoandrost-4-en (7). NaBH4 (42 mg, 1.1 mmol) was added at 
room temperature to a solution of 6 (124 mg, 0.36 mmol) in CH3OH (50 mL) in one portion. After 30 
min, the reaction was stopped. The solution was neutralized with 1 M HCl. After evaporation of the 
majority of MeOH under reduced pressure, the residue was extracted with ethyl acetate (15 mL × 3). 
The organic layer was washed with cold water and saturated brines. After drying over anhydrous 
sodium sulfate, the solvent was removed under reduced pressure and a crude product was obtained. 
After recrystallization from methanol, 95 mg (78%) of compound 7 was obtained as a white solid. θ mp 
198–200 °C; IR (KBr) ν/cm−1: 3331, 2941, 2866, 1654, 1442, 1384, 1217, 1131; 1H-NMR (CDCl3, 
300 MHz) δ: 0.703 (3H, s, 18-CH3), 1.008 (3H, s, 19-CH3), 1.988 (3H, s, N-COCH3), 3.57–3.47 (1H, 
m, C3-H), 3.93–3.80 (1H, m, C6-H), 4.13 (1H, dd, J = 7.0, 1.5, C17-H), 5.36 (1H, d, J = 2.1, C4-H), 
5.40 (1H, br s, N-H); 13C-NMR (CDCl3, 75 MHz) δ: 170.0 (-NHCOCH3), 140.9 (5-C), 121.3 (4-C), 
71.6 (6-C), 68.8 (3-C), 58.9 (17-C), 52.8 (14-C), 50.1 (9-C), 42.7 (13-C), 42.2 (7-C), 37.2 (10-C), 36.8 
(1-C), 36.5 (12-C), 32.1 (8-C), 31.6 (2-C), 31.5 (16-C), 28.7 (15-C), 23.6 (21-C), 20.6 (11-C), 19.4 
(19-C), 12.0 (18-C); ESI-MS m/z: 348 (M+1)+.  
Synthesis of 3-hydroxy-17-acetamidoandrost-4-en-6-one (8). NaBH4 (42 mg, 1.1 mmol) was added to 
a solution of 6 (124 mg, 0.36 mmol) and NiCl2·6H2O (87 mg, 0.37 mmol) in CH3OH (15 mL) in the 
interval of 5 min at room temperature. After 5 min, the reaction was stopped. The solution was 
neutralized with 1 M HCl. After evaporation of the majority of MeOH under reduced pressure, water 
of 15 mL was added. Then the residue was extracted with ethyl acetate (15 × 3 mL). The resulting 
solution was washed with cold water and saturated brine. After drying over anhydrous sodium sulfate, 
the solvent was removed under reduced pressure, and the resulting crude product was purified by flash 
chromatography on silica gel using methanol/dichloromethane (20:1) as the eluent. Compound 8 was 
obtained as white solid (75 mg, 60%), θ mp 187–188 °C; IR(KBr) ν/cm–1: 3330, 2942, 2865, 1675, 
1442, 1385, 1218; 1H-NMR (CDCl3, 300 MHz) δ: 0.747 (3H, s, 18-CH3), 1.196 (3H, s, 19-CH3), 2.004 
(3H, s, N-COCH3), 2.22–2.14 (2H, m, C16-H), 2.418 (1H, dd, J = 12.9, 4.5, C7-αH), 3.929 (1H, q,  
J = 9.0, C17-H), 4.338 (1H, ddd, J = 11.4, 4.2, 1.2, C3-βH), 5.330 (1H, br d, J = 7.5, N-H), 6.196 (1H, d, 
J = 1.2, C4-H); 13C-NMR (CDCl3, 75 MHz) δ: 199.3 (6-C), 170.0 (-NHCO), 169.9 (5-C), 119.9 (4-C), 
68.5 (3-C), 58.6 (17-C), 53.7 (9-C), 51.7 (14-C), 42.9 (13-C), 40.9 (7-C), 39.0 (10-C), 36.5 (8-C), 36.3 
(1-C), 34.3 (12-C), 33.7 (2-C), 28.6 (16-C), 23.6 (15-C), 23.5 (21-C), 20.6 (11-C), 18.3 (19-C), 12.1 
(18-C); ESI-MS m/z: 346 (M+1)+. 
Synthesis of N,N-dimethyl-3,12-dioxo-7-deoxycholic amide (11). Oxalyl chloride (200 µL, 2.23 mmol) 
was added to a solution of 10 (535 mg, 1.38 mmol) and pyridine (150 µL, 1.80 mmol) in toluene (25 
mL) at ice bath temperature. The mixture was stirred for 2 h. After completion of the reaction as 
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indicated by TLC, a solution of dimethyl amine (540 µL) was added dropwise. The solution was 
stirred for 10 min at 0 °C and 10 mL ice water was added to the solution. The solution was extracted 
with dichloromethane (30 × 3 mL). The organic solution was washed with cold water and saturated 
brine. After drying over anhydrous sodium sulfate, the solvent was removed under reduced pressure, 
and the resulting crude product was purified by chromatography on silica gel using petroleum/ethyl 
acetate (1:2) as the eluent. Compound 11 was obtained as a white solid (480 mg, 71%), θ mp 
271–272 °C; IR(KBr) ν/cm–1: 2929, 2859, 1695, 1634; 1H-NMR (CDCl3, 300 MHz) δ: 0.797 (3H, d,  
J = 5.7, 21-CH3), 1.000 (3H, s, 18-CH3), 1.050 (3H, s, 19-CH3), 2.13–2.04 (2H, m), 2.37–2.18 (3H, m), 
2.58–2.48 (2H, m, C11-H), 2.872 (3H, s, NCH3), 2.955 (3H, s, NCH3); 13C-NMR (CDCl3, 75 MHz) δ: 
214.2 (12-C), 212.1 (3-C), 173.4 (24-C), 58.5 (14-C), 57.5 (17-C), 46.5 (9-C), 44.2 (13-C), 43.6 (5-C), 
42.1 (4-C), 38.3 (8-C), 37.3 (11-C), 36.8 (1-C), 36.7 (2-C), 35.6 (10-C), 35.5 (N-C), 35.4 (N-C), 35.3 
(20-C), 30.6 (7-C), 30.2 (23-C), 27.4 (22-C), 26.5 (15-C), 25.4 (6-C), 24.3 (16-C), 22.1 (21-C), 18.7 
(19-C), 11.7 (18-C); ESI-MS m/z: 416 (M+1)+. 
Synthesis of N,N-dimethyl-3-hydroxy-12-oxo-7-deoxycholic amide (12). Compound 12 was prepared 
according to the procedure of 7. Yield 30%, θ mp 279–280 °C; IR(KBr) ν/cm–1: 3465, 2925, 2859, 1707, 
1621; 1H-NMR (CDCl3, 300 MHz) δ: 0.843 (3H, d, J = 6.3, 21-CH3), 0.986 (3H, s, 19-CH3), 0.995 
(3H, s, 18-CH3), 2.26–2.17 (3H, m), 2.49-2.32 (2H, m, C11-H), 2.912 (3H, s, NCH3), 2.994 (3H, s, 
NCH3), 3.63-3.53 (1H, m, C3-H); 13C-NMR (CDCl3, 75 MHz) δ: 215.2 (12-C), 173.7 (24-C), 71.2 
(3-C), 58.7 (14-C), 57.5 (17-C), 46.4 (13-C), 44.1 (5-C), 41.5 (9-C), 38.1 (8-C), 37.3 (11-C), 36.3 
(1-C), 35.6 (4-C), 35.4 (10-C), 35.3 (N-C), 35.3 (N-C), 35.2 (20-C), 30.6 (2-C), 30.3 (23-C), 30.2 
(22-C), 27.5 (6-C), 27.1 (15-C), 26.1 (16-C), 24.3 (7-C), 22.8 (21-C), 18.8 (18-C), 11.7 (19-C); 
ESI-MS m/z: 418 (M+1)+. 
Synthesis of N,N-dimethyl-3-acetoxy-12-oxo-7-deoxycholic amide (13). Compound 13 was prepared by 
the esterification of 12 using acetic anhydride in pyridine. Yield: 78%. θ mp 153–154 °C; IR(KBr) 
ν/cm–1: 3440, 2953, 1730, 1700, 1656, 1465, 1447; 1H-NMR (CDCl3, 300 MHz) δ: 0.885 (3H, d,  
J = 6.3, 21-CH3), 1.035 (6H, br s, 18-CH3 and 19-CH3), 2.025 (3H, s, CH3CO-), 2.951 (3H, s, NCH3), 
3.025 (3H, s, NCH3), 4.659–4.763 (1H, m, C3-H); 13C-NMR (CDCl3, 75 MHz) δ: 214.9 (12-C), 173.6 
(24-C), 170.6 (CH3CO-), 73.7 (3-C), 58.7 (14-C), 57.6 (17-C), 46.5 (13-C), 44.1 (5-C), 41.4 (9-C), 
38.1 (8-C). 37.3 (11-C), 35.7 (1-C), 35.4 (4-C), 35.3 (N-C), 34.9 (N-C), 32.1 (20-C), 30.7 (2-C), 30.3 
(23-C), 27.5 (10-C), 26.9 (22-C), 26.4 (6-C), 26.4 (15-C), 24.4 (16-C), 22.7 (7-C), 21.4 (21-C), 18.8 
(18-C), 11.7 (19-C); ESI-MS m/z: 460 (M+1)+. 
Synthesis of N,N-dimethyl-3-hydroxy-12-thiosemicarbazone-7-deoxycholic amide (14). The compound 
12 (100 mg, 0.24 mmol) was dissolved in 15 mL of CH3CH2OH and the solution was adjusted to  
pH ≈ 3–5 by adding a few drops of glacial acetic acid. After the solution was heated to 80 °C, and 
thiosemicarbazide (32 mg, 0.36 mmol) was added. The mixture was stirred for 10 h at 80 °C until no 
starting material (the progress of the reaction was monitored by TLC). Then the reaction was 
terminated and the majority of solvent was evaporated under reduced pressure. Water (10 mL) was 
added to the mixture which was then extracted with dichloromethane. The organic layer was washed 
with water and saturated brine. After drying over anhydrous sodium sulfate, the solvent was removed 
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under reduced pressure, and the resulting crude product was purified by flash chromatography on silica 
gel using dichloromethane/methanol (40:1) as the eluent to give 56 mg of 14 as a white solid (yield: 
49%), θ mp 294–295 °C; IR (KBr) ν/cm–1: 3427, 2921, 1634, 1503, 1401; 1H-NMR (CDCl3, 300 MHz): 
0.843 (3H, d, J = 6.3, 21-CH3), 0.986 (3H, s, 18-CH3), 0.995 (3H, s, 19-CH3), 2.912 (3H, s, N-CH3), 
2.994 (3H, s, N-CH3), 3.577 (1H, m, C3-H), 6.576 (1H, br s, -NH2), 7.234 (1H, br s, -NH2), 9.284 (1H, 
s, -NH-); 13C-NMR (CDCl3, 75 MHz): 178.8 (C=S), 173.6 (24-C), 162.6 (12-C), 71.1 (3-C), 58.7 
(14-C), 57.5 (17-C), 46.4 (13-C), 44.1 (5-C), 41.6 (9-C), 38.1 (8-C), 37.4 (4-C), 36.3 (11-C), 35.7 (10-C), 
35.6 (1-C), 35.4 (N-C), 35.3 (20-C), 35.1 (N-C), 30.7 (2-C), 30.3 (22-C), 30.2 (23-C), 27.5 (6-C), 27.1 
(15-C), 26.1 (16-C), 24.4 (7-C), 22.8 (21-C), 18.8 (18-C), 11.7 (19-C); ESI-MS m/z: 491(M+1)+. 
Synthesis of N,N-dimethyl-3-hydroximino-12-oxo-7-deoxycholic amide (15). Compound 11 (91 mg, 
0.22 mmol) was dissolved in 95% CH3CH2OH (15 mL). After the mixture was heated to 70 °C, 
CH3COONa·3H2O (30 mg, 0.22 mmol) and NH2OH·HCl (18 mg, 0.26 mmol) were added. The 
mixture was stirred for 3 h at 70 °C. Then the reaction was terminated and the majority of solvent was 
evaporated under reduced pressure. Distilled water was added into the reaction mixture, and the 
product was extracted with dichloromethane. The combined extracts were washed with water and 
saturated brine, dried with anhydrous sodium sulfate, and evaporated under reduced pressure. The 
residue was purified by flash chromatography on silica gel using dichloromethane/methanol (40:1) as 
the eluent. Compound 15 was obtained as a white solid (56 mg, 60%). θmp 232–233 °C; IR (KBr) 
ν/cm–1: 3440, 1691, 1601, 1437, 1392; 1H-NMR (CDCl3, 300 MHz): 0.853 (3H, d, J = 6.3, 21-CH3), 
1.025 (3H, s, 18-CH3), 1.035 (3H, s, 19-CH3), 2.534 (2H, m, C11-H), 2.923 (3H, s, N-CH3), 2.999 (3H, 
s, N-CH3), 3.070 (1H, dd, J = 14.4, 3.9, C2-βH); 13C-NMR (CDCl3, 75 MHz): 214.9 (12-C), 173.7 
(24-C), 160.2 (3-C), 58.6 (14-C), 57.6 (17-C), 46.4 (9-C), 44.2 (5-C), 44.0 (13-C), 43.3 (10-C), 41.9 
(8-C), 38.3 (11-C), 37.4 (N-C), 36.9 (N-C), 36.1 (20-C), 35.6 (7-C), 35.5 (4-C), 30.6 (23-C), 30.3 
(6-C), 27.4 (22-C), 26.6 (2-C), 26.5 (1-C), 25.6 (15-C), 24.8 (16-C), 24.3 (21-C), 22.6 (19-C), 18.8 
(18-C); ESI-MS m/z: 431(M+1)+. 
Synthesis of N,N-dimethyl-3-thiosemicarbazone-12-oxo-7-deoxycholic amide (16). Compound 16 was 
prepared similarly to 14, but from the compound 11. Yield: 69%, θmp 282–283 °C. IR (KBr) ν/cm–1: 3432, 
2929, 2868, 1703, 1638, 1499; 1H-NMR (CDCl3, 300 MHz): 0.856 (3H, d, J = 5.7, 21-CH3), 1.034 
(3H, s, 18-CH3), 1.060 (3H, s, 19-CH3), 2.539 (2H, m, C11-H), 2.926 (3H, s, N-CH3), 3.002 (3H, s, 
N-CH3), 6.487 (1H, br s, N-H), 7.213 (H, br s, N-H), 8.873 (1H, s, -NH-); 13C-NMR (CDCl3, 75 
MHz,): 214.5 (12-C), 178.7 (S=C), 173.6 (24-C), 156.8 (3-C), 58.5 (14-C), 57.5 (17-C), 46.5 (9-C), 
44.4 (5-C), 44.1 (13-C), 43.7 (10-C), 42.3 (8-C), 38.3 (11-C), 37.3 (N-C), 36.1 (N-C), 36.0 (20-C), 
35.6 (4-C), 35.4 (7-C), 30.6 (23-C), 30.3 (6-C), 29.9 (2-C), 27.4 (22-C), 26.7 (1-C), 25.6 (15-C), 24.3 
(16-C), 22.5 (21-C), 18.8 (19-C), 11.8 (18-C); ESI-MS m/z: 489 (M+1)+.  
Compounds 17 and 18 were prepared similarly according to the procedure of 15, but CH3ONH2·HCl 
and PhCH2ONH2·HCl were used as reagents instead of NH2OH·HCl. 
N,N-dimethyl-3-O-methyloximino-12-oxo-7-deoxycholic amide (17). Yield: 70%, θmp 188–189 °C. IR 
(KBr) ν/cm–1: 3436, 2855, 1703, 1654, 1446, 1041; 1H-NMR (CDCl3, 300 MHz): 0.875 (3H, d, J = 6.3, 
21-CH3), 1.043 (3H, s, 18-CH3), 1.054 (3H, s, 19-CH3), 2.55–2.40 (2H, m, C11-H), 2.940 (3H, s, 
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N-CH3), 3.014 (3H, s, N-CH3), 3.804 (3H, s, O-CH3); 13C-NMR (CDCl3, 75MHz): 214.7 (12-C), 173.5 
(24-C), 160.0 (3-C), 61.0 (-OCH3), 58.6 (14-C), 57.6 (17-C), 46.5 (9-C), 44.2 (13-C), 44.0 (10-C), 
43.5 (5-C), 42.0 (8-C), 38.3 (11-C), 37.3 (N-C), 36.1 (N-C), 36.0 (20-C), 35.6 (4-C), 35.4 (7-C), 30.6 
(23-C), 30.2 (6-C), 27.4 (22-C), 26.7 (2-C), 26.6 (1-C), 25.6 (15-C), 24.3 (16-C), 22.6 (21-C), 18.8 
(19-C), 11.7 (18-C); ESI-MS m/z: 445 (M+1)+. 
N,N-dimethyl-3-O-benzyloximino-12-oxo-7-deoxycholic amide (18). Yield: 72%, θmp 148–149 °C. IR 
(KBr) ν/cm–1: 2970, 2868, 1707, 1625, 1450, 1397; 1H-NMR (CDCl3, 300 MHz): 0.882 (3H, d, J = 6.3, 
21-CH3), 1.048 (3H, s, 18-CH3), 1.056 (3H, s, 19-CH3), 2.35–2.45 (1H, m, C11-βH), 2.553 (1H, t,  
J = 12.6, C11-αH), 2.947 (3H, s, N-CH3), 3.019 (3H, s, N-CH3), 5.052 (2H, s, O-CH2-Ph), 7.36–7.29 
(5H, m, -C6H5); 13C-NMR (CDCl3, 75 MHz): 214.7 (12-C), 173.5 (24-C), 160.5 (3-C), [138.2, 128.3, 
128.3, 127.9, 127.8, 127.6 (-C6H5)], 75.2 (O-C), 58.6 (14-C), 57.5 (17-C), 46.5 (9-C), 44.3 (13-C), 
44.0 (5-C), 43.5 (10-C), 41.9 (8-C), 38.3 (11-C), 37.3 (N-C), 36.1 (N-C), 36.0 (20-C), 35.6 (2-C), 35.4 
(7-C), 30.6 (23-C), 30.3 (6-C), 27.4 (1-C), 26.6 (22-C), 25.8 (4-C), 25.6 (15-C), 24.3 (16-C), 22.6 
(21-C), 18.8 (19-C), 11.8 (18-C); ESI-MS m/z: 521 (M+1)+. 
4. Conclusions 
We have prepared some 17-acetamidoandrostane and N,N-dimethyl-7-deoxycholic amide derivatives 
with different substitutent groups on different positions of the steroidal nucleus. The antiproliferative 
activity of the synthesized compounds against the SGC 7901 and Bel 7404 cell lines was assayed. The 
results showed that the blockage of the interaction of the amide group with outside groups might  
cause a decrease of the cytotoxicity, and an O-benzyloxime group on the 3-position of 
N,N-dimethyl-7-deoxycholic amide could enhance the cytotoxic activity of the compound. Our result 
revealed some structure-activity relationships of the compounds and although some displayed 
indistinctive cytotoxicity against these cancer cells, this informstion may be useful for the design of 
novel chemotherapeutic drugs with better activity. 
Acknowledgments 
The authors acknowledge the financial support of the Natural Science Foundation of Guangxi 
Province (No. 2010GXNSFA013019, No. 2010GXNSFD013052) and Natural Science Fund of 
Education Department of Guangxi Province (No. 201202ZD059). 
Conflict of Interest 
The authors declare no conflict of interest. 
References 
1. Aggarwal, S.; Thareja, S.; Verma, A.; Bhardwaj, T.R.; Kumar, M. An overview on 5-reductase 
inhibitors. Steroids 2010, 75, 109–153. 
2. Li, H.J.; Jiang, Y.; Li, P. Chemistry, bioactivity and geographical diversity of steroidal alkaloids 
from the Liliaceae family. Nat. Prod. Rep. 2006, 23, 735–752. 
Molecules 2013, 18 7446 
 
3. Ifere, G.O.; Barr, E.; Equan, A.; Gordon, K.; Singh, U.P.; Jaideep Chaudhary, J.; Igietseme, J.U.; 
Ananaba, G.A. Differential effects of cholesterol and phytosterols on cell proliferation, apoptosis 
and expression of a prostate specific gene in prostate cancer cell lines. Cancer Detect. Prev. 2009, 
32, 319–328. 
4. Trafalis, D.T.P. Hybrid aza-steroid alkylators in the treatment of colon cancer. Cancer Lett. 2006, 
243, 202–210. 
5. Krstić, N.M.; Mira, S.; Bjelaković, M.S.; Žižak, Ž.; Pavlović, M.D.; Juranić, Z.D.; Vladimir, D.; 
Pavlović, V.D. Synthesis of some steroidal oximes, lactams, thiolactams and their anti-tumor 
activities. Steroids 2007, 72, 406–414. 
6. Koutsourea, A.I.; Fousteris, M.A.; Arsenou, E.S.; Papageorgiou, A.; George, N.; Pairas, G.N.; Sotiris, 
S.; Nikolaropoulos, S.S. Rational design, synthesis, and in vivo evaluation of the antileukemic activity 
of six new alkylating steroidal esters. Bioorg. Med. Chem. 2008, 16, 5207–5215. 
7. Trafalis, D.T.P.; Geromichalos, G.D.; Koukoulitsa, C.; Papageorgiou, A.; Karamanakos, P.; 
Camoutsis, C. Lactandrate: A D-homo-aza-androsterone alkylator in the treatment of breast cancer. 
Breast Can. Res. Treat. 2006, 97, 17–31. 
8. Dhingra, N.; Bhardwaj, T.R.; Mehta, N.; Mukhopadhyay, T.; Kumar, A.; Kumar, M. Synthesis, 
antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly 
synthesized steroidal lactams. Europ. J. Med. Chem. 2010, 45, 2229–2236. 
9. Catsoulacos, P.; Politis, D.; Wampler, G.L. Antitumor activity of homo aza-steroidal ester of 
[p-bis(2-chloroethyl)amino]phenyl acetic acid and [p-bis(2-chloroethyl)amino] phenyl butyric 
acid. Cancer Chemother. Pharmacol. 1983, 10, 129–132. 
10. Catsoulacos, P.; Catsoulacos, D. Antitumor activity of homo-aza-steroidal esters of 
p-N,N-bis(2-chloroetheryl)amino phenoxy acetic acid. Anticancer Res. 1993, 14, 1203–1208. 
11. Huang, Y.M.; Chen, S.J.; Cui, J.G.; Gan, C.F.; Liu Z.P.; Wei, Y.L.; Song, H.C. Synthesis and 
cytotoxicity of A-homo-lactam derivatives of cholic acid and 7-deoxycholic acid. Steroids 2011, 
76, 690–694. 
12. Huang, Y.M.; Cui, J.G.; Zhong, Z.G.; Gan, C.F.; Zhang, W.Y.; Song, H.C. Cytotoxicity of 
17a-Aza-D-homo-androster-17-one derivatives. Bioorg. Med. Chem. Let. 2011, 21, 3641–3643. 
13. Huang, Y.M.; Cui, J.G.; Chen, S.J.; Gan, C.F.; Zhou, A.M. Synthesis and antiproliferative activity 
of some steroidal lactams. Steroids 2011, 76, 1346–1350. 
14. Huang, Y.M.; Cui, J.G.; Chen, S.J.; Gan, C.F.; Yao, Q.C.; Lin, Q.F. Synthesis and antiproliferative 
activity of C-Homo-Lactam derivatives of 7-deoxycholic acid. Bioorg. Med. Chem. Lett. 2013, 23, 
2265–2267. 
15. Huang, Y.M.; Cui, J.G.; Zheng Q.X.; Zeng, C.; Chen, Q.; Zhou, A.M. 
6-hydroximino-4-aza-A-homo-cholest-3-one is a potent inducer of apoptosis in cancer cells. 
Steroids 2012, 77, 829–834. 
16. Steiner, J.F. Finasteride: A 5 alpha-reductase inhibitor. Clin. Pharm. 1993, 12, 15–23. 
17. Peters, D.H.; Sorkin, E.M. Finasteride: A review of its potential in the treatment of benign 
prostatic hyperplasia. Drugs 1993, 46, 177–208. 
18. Zeng, L.M.; Li, X.Q.; Su, J.Y.; Fu, X.; Schmitz, F.J. A new cytotoxic dihydroxy sterol from the 
soft coral alcyonium patagonicum. J. Nat. Prod. 1995, 58, 296–298. 
Molecules 2013, 18 7447 
 
19. Cui, J.; Huang, Y.M.; Chen, S.J.; Zhou, A.M. 6-Substituted-4-aza-A-homo-3-oxysteroids as 
antitumor drugs. Patent CN 201110009124.2, 2011. 
20. Chen, S.J.; Zhang, X.J.; Jia, L.Y.; Cui, J.G. Synthesis of some cholic acid and deoxycholic acid 
oximes. Chem. Res. Appl. 2010, 22, 848–852. 
Sample Availability: Samples of the compound 4, 5, 11, 12 are available from the authors. 
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
